Anavex Life Sciences Corp - ESG Rating & Company Profile powered by AI
This Disclosure score includes seventeen United Nations SDGs including: 'Gender Equality', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'. Full Sustainability analysis of Anavex Life Sciences Corp are accessed by signing up for free. If you are employed by Anavex Life Sciences Corp and you wish to use your ESG rating, please get in touch.
Anavex Life Sciences Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 2.0, social score of 4.8 and governance score of 6.4.
4.4
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
868 | Trevena Inc | 4.5 | High |
868 | Urogen Pharma Ltd | 4.5 | High |
910 | Anavex Life Sciences Corp | 4.4 | High |
910 | CanBas Co Ltd | 4.4 | High |
910 | CNS Pharmaceuticals Inc | 4.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Anavex Life Sciences Corp have an accelerator or VC vehicle to help deliver innovation?
Does Anavex Life Sciences Corp disclose current and historical energy intensity?
Does Anavex Life Sciences Corp report the average age of the workforce?
Does Anavex Life Sciences Corp reference operational or capital allocation in relation to climate change?
Does Anavex Life Sciences Corp disclose its ethnicity pay gap?
Does Anavex Life Sciences Corp disclose cybersecurity risks?
Does Anavex Life Sciences Corp offer flexible work?
Does Anavex Life Sciences Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Anavex Life Sciences Corp disclose the number of employees in R&D functions?
Does Anavex Life Sciences Corp conduct supply chain audits?
Does Anavex Life Sciences Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Anavex Life Sciences Corp conduct 360 degree staff reviews?
Does Anavex Life Sciences Corp disclose the individual responsible for D&I?
Does Anavex Life Sciences Corp disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Anavex Life Sciences Corp disclose current and / or historical scope 2 emissions?
Does Anavex Life Sciences Corp disclose water use targets?
Does Anavex Life Sciences Corp have careers partnerships with academic institutions?
Did Anavex Life Sciences Corp have a product recall in the last two years?
Does Anavex Life Sciences Corp disclose incidents of discrimination?
Does Anavex Life Sciences Corp allow for Work Councils/Collective Agreements to be formed?
Has Anavex Life Sciences Corp issued a profit warning in the past 24 months?
Does Anavex Life Sciences Corp disclose parental leave metrics?
Does Anavex Life Sciences Corp disclose climate scenario or pathway analysis?
Does Anavex Life Sciences Corp disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Anavex Life Sciences Corp disclose the pay ratio of women to men?
Does Anavex Life Sciences Corp support suppliers with sustainability related research and development?
Does Anavex Life Sciences Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Anavex Life Sciences Corp reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Anavex Life Sciences Corp involved in embryonic stem cell research?
Does Anavex Life Sciences Corp disclose GHG and Air Emissions intensity?
Does Anavex Life Sciences Corp disclose its waste policy?
Does Anavex Life Sciences Corp report according to TCFD requirements?
Does Anavex Life Sciences Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Anavex Life Sciences Corp disclose energy use targets?
Does Anavex Life Sciences Corp disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Anavex Life Sciences Corp have a policy relating to cyber security?
Have a different question?
Potential Risks for Anavex Life Sciences Corp
These potential risks are based on the size, segment and geographies of the company.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.